As of 31 July 2023, the National Clinical Evidence Taskforce is no longer funded. The COVID-19 and MPX guidelines are still accessible online, but are not currently being updated.
For more information and the latest developments in Australian living evidence visit livingevidence.org.au
The National Clinical Evidence Taskforce is a multi-disciplinary collaboration of 35 member organisations – Australia’s medical colleges and peak health organisations – who share a commitment to provide national evidence-based treatment guidelines for urgent and emerging diseases.
This pioneering alliance established the world’s first ‘living guidelines’ for the care of people with COVID-19 and MPX.
Funding has now been discontinued for the National Clinical Evidence Taskforce and the COVID-19 guidelines as of 30 June 2023.
These guidelines are no longer continually updated but will remain online until the guidance becomes inaccurate and/or no longer reflects the evidence or recommended practice.
We congratulate and thank our 35 member organisations together with our 250+ clinical and consumer contributors for their extraordinary collaborative efforts over the last three years to develop these guidelines. You can find more information on NCET’s achievements at evidenceinaction.org.
We also acknowledge the generosity of our funders without whom this critical work would not have been possible.
Evidence summaries for relevant diseases in Australia
Your views help us to identify and prioritise questions to include in the living guideline.
Submit your questions here
Subscribe here to receive regular updates from the Taskforce
